Current anticoagulant safety

Bibliography

• Hirsh J, Bauer KA, Donati MB, Parenteral anticoagulants: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008;133(6 Suppl):141S-59S
   PubMed Web of Science ®Google Scholar
• Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972;287(7):324-7
   PubMed Web of Science ®Google Scholar
• Baker BA, Adelman MD, Smith PA, Osborn JC. Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays. Arch Intern Med 1997;157(21):2475-9
   PubMed Web of Science ®Google Scholar
• Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. BMJ 1994;309(6950):299-304
   PubMed Web of Science ®Google Scholar
• Palareti G, Leali N, Coccheri S, Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996;348(9025):423-8
   PubMed Web of Science ®Google Scholar
• Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120(11):897-902
   PubMed Web of Science ®Google Scholar
• Fang MC, Chang Y, Hylek EM, Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004;141(10):745-52
   PubMed Web of Science ®Google Scholar
• Cannegieter SC, Rosendaal FR, Wintzen AR, Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;333(1):11-17
   PubMed Web of Science ®Google Scholar
• Pengo V, Crippa L, Falanga A, Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 2011;106(5):868-76
   PubMed Web of Science ®Google Scholar
• Tripodi A, Chantarangkul V, Guinet C, Samama MM. The International normalized ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost 2011;9(1):226-8
   PubMed Web of Science ®Google Scholar
• van Ryn J, Stangier J, Haertter S, Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103(6):1116-27
   PubMed Web of Science ®Google Scholar
• Hillarp A, Baghaei F, Fagerberg Blixter I, Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011;9(1):133-9
   PubMed Web of Science ®Google Scholar
• Keeling D. Duration of anticoagulation: decision making based on absolute risk. Blood Rev 2006;20(3):173-8
   PubMed Web of Science ®Google Scholar
• Campbell NR, Hull RD, Brant R, Aging and heparin-related bleeding. Arch Intern Med 1996;156(8):857-60
   PubMed Web of Science ®Google Scholar
• Pengo V, Legnani C, Noventa F, Palareti G. Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A multicenter inception cohort study. Thromb Haemost 2001;85(3):418-22
   PubMed Web of Science ®Google Scholar
• Arnsten JH, Gelfand JM, Singer DE. Determinants of compliance with anticoagulation: a case-control study. Am J Med 1997;103(1):11-17
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Wallentin L, Connolly SJ, Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011;123(21):2363-72
   PubMed Web of Science ®Google Scholar
• Sam C, Massaro JM, D'Agostino RB Sr, Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study). Am J Cardiol 2004;94(7):947-51
   PubMed Web of Science ®Google Scholar
• Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):257S-98S
   PubMed Web of Science ®Google Scholar
• DiMarco JP, Flaker G, Waldo AL, Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005;149(4):650-6
   PubMed Web of Science ®Google Scholar
• Vecsler M, Loebstein R, Almog S, Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost 2006;95(2):205-11
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Bevans CG, Fregin A, Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost 2007;98(3):570-8
   PubMed Web of Science ®Google Scholar
• Reinecke H, Brand E, Mesters R, Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009;20(4):705-11
   PubMed Web of Science ®Google Scholar
• Holbrook AM, Pereira JA, Labiris R, Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165(10):1095-106
   PubMed Web of Science ®Google Scholar
• Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996;276(10):811-15
   PubMed Web of Science ®Google Scholar
• Dentali F, Douketis JD, Lim W, Crowther M. Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med 2007;167(2):117-24
   PubMed Web of Science ®Google Scholar
• Hart RG, Benavente O, Pearce LA. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis. Cerebrovasc Dis 1999;9(4):215-17
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345(7):494-502
   PubMed Web of Science ®Google Scholar
• Schalekamp T, Klungel OH, Souverein PC, de Boer A. Effect of oral antiplatelet agents on major bleeding in users of coumarins. Thromb Haemost 2008;100(6):1076-83
   PubMed Web of Science ®Google Scholar
• Halg C, Brunner-La Rocca HP, Kaiser C, Early and late increased bleeding rates after angioplasty and stenting due to combined antiplatelet and anticoagulanttherapy. EuroIntervention 2009;5(4):425-31
   PubMedGoogle Scholar
• Gilard M, Blanchard D, Helft G, Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting (from STENTIng and oral antiCOagulants [STENTICO]). Am J Cardiol 2009;104(3):338-42
   PubMed Web of Science ®Google Scholar
• Nguyen MC, Lim YL, Walton A, Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent? Eur Heart J 2007;28(14):1717-22
   PubMed Web of Science ®Google Scholar
• Orford JL, Fasseas P, Melby S, Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J 2004;147(3):463-7
   PubMed Web of Science ®Google Scholar
• Ruiz-Nodar JM, Marin F, Sanchez-Paya J, Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation. Eur Heart J 2009;30(8):932-9
   PubMed Web of Science ®Google Scholar
• Steffensen FH, Kristensen K, Ejlersen E, Major haemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort. J Intern Med 1997;242(6):497-503
   PubMed Web of Science ®Google Scholar
• Hylek EM, Evans-Molina C, Shea C, Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115(21):2689-96
   PubMed Web of Science ®Google Scholar
• Connolly S, Pogue J, Hart R, Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367(9526):1903-12
   PubMed Web of Science ®Google Scholar
• Landefeld CS, McGuire E III, Rosenblatt MW. A bleeding risk index for estimating the probability of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1990;89(5):569-78
   PubMed Web of Science ®Google Scholar
• Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998;105(2):91-9
   PubMed Web of Science ®Google Scholar
• Kuijer PM, Hutten BA, Prins MH, Buller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999;159(5):457-60
   PubMed Web of Science ®Google Scholar
• Gage BF, Yan Y, Milligan PE, Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006;151(3):713-19
   PubMed Web of Science ®Google Scholar
• Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011;57(2):173-80
   PubMed Web of Science ®Google Scholar
• Pisters R, Lane DA, Nieuwlaat R, A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138(5):1093-100
   PubMed Web of Science ®Google Scholar
• Cannon CP, Battler A, Brindis RG, American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol 2001;38(7):2114-30
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3(4):692-4
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Kastrati A, Berger PB. Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. Am Heart J 2007;154(1):3-11
   PubMed Web of Science ®Google Scholar
• Rao AK, Pratt C, Berke A, Thrombolysis in Myocardial Infarction (TIMI) Trial–phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11(1):1-11
   PubMed Web of Science ®Google Scholar
• Bovill EG, Terrin ML, Stump DC, Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 1991;115(4):256-65
   PubMed Web of Science ®Google Scholar
• Antman EM, McCabe CH, Gurfinkel EP, Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999;100(15):1593-601
   PubMed Web of Science ®Google Scholar
• The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329(10):673-82
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Mehta SR, Anand SS, Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006;114(8):774-82
   PubMed Web of Science ®Google Scholar
• James S, Akerblom A, Cannon CP, Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009;157(4):599-605
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Borris LC, Friedman RJ, Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358(26):2765-75
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Brenner B, Dahl OE, Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372(9632):31-9
   PubMed Web of Science ®Google Scholar
• Lassen MR, Ageno W, Borris LC, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358(26):2776-86
   PubMed Web of Science ®Google Scholar
• Turpie AG, Lassen MR, Davidson BL, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009;373(9676):1673-80
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Rosencher N, Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5(11):2178-85
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Rosencher N, Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370(9591):949-56
   PubMed Web of Science ®Google Scholar
• Ginsberg JS, Davidson BL, Comp PC, Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24(1):1-9
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Huo MH, Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011;105(4):721-9
   PubMed Web of Science ®Google Scholar
• Rao SV, Eikelboom JA, Granger CB, Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28(10):1193-204
   PubMed Web of Science ®Google Scholar
• van Dongen CJ, van den Belt AG, Prins MH, Lensing AW. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2004(4):CD001100
   Google Scholar
• Erkens PM, Prins MH. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2010(9):CD001100
   Google Scholar
• Cook DJ, Rocker G, Meade M, Prophylaxis of thromboembolism in critical care (PROTECT) trial: a pilot study. J Crit Care 2005;20(4):364-72
   PubMed Web of Science ®Google Scholar
• Lip GY, Andreotti F, Fauchier L, Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European heart rhythm association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace 2011;13(5):723-46
   PubMed Web of Science ®Google Scholar
• Gullov AL, Koefoed BG, Petersen P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial fibrillation aspirin and anticoagulation. Arch Intern Med 1999;159(12):1322-8
   PubMed Web of Science ®Google Scholar
• Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362(9397):1691-8
   PubMed Web of Science ®Google Scholar
• Albers GW, Diener HC, Frison L, Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005;293(6):690-8
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12):1139-51
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(10):883-91
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365(11):981-92
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361(24):2342-52
   PubMed Web of Science ®Google Scholar
• Turpie AG, Lassen MR, Kakkar A, Pooled analysis of four studies of rivaroxaban: effect on symptomatic events and bleeding and the influence of clinically relevant patient subgroups. Available at: http://meeting.chestpubs.org/cgi/content/abstract/136/4/144S-a Chest 2009;136(4):144S-a
   Google Scholar
• Lassen MR, Raskob GE, Gallus A, Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009;361(6):594-604
   PubMed Web of Science ®Google Scholar
• Lassen MR, Raskob GE, Gallus A, Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010;375(9717):807-15
   PubMed Web of Science ®Google Scholar
• Lassen MR, Gallus A, Raskob GE, Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010;363(26):2487-98
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJV, Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365(11):981-92
   PubMed Web of Science ®Google Scholar
• Wolzt M, Weltermann A, Nieszpaur-Los M, Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man. Thromb Haemost 1995;73(3):439-43
   PubMed Web of Science ®Google Scholar
• Bijsterveld NR, Moons AH, Boekholdt SM, Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002;106(20):2550-4
   PubMed Web of Science ®Google Scholar
• Denas G, Marzot F, Offelli P, Effectiveness and safety of a management protocol to correct over-anticoagulation with oral vitamin K: a retrospective study of 1,043 cases. J Thromb Thrombolysis 2009;27(3):340-7
   PubMed Web of Science ®Google Scholar
• Denas G, Cucchini U, Iliceto S, Pengo V. An oral vitamin K protocol to reverse over-anticoagulation in patients presenting with an International normalised ratio above 10.0. Thromb Haemost 2009;101(2):410-11
   PubMed Web of Science ®Google Scholar
• Crowther MA, Ageno W, Garcia D, Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med 2009;150(5):293-300
   PubMed Web of Science ®Google Scholar
• Makris M, van Veen JJ, Maclean R. Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient. J Thromb Thrombolysis 2010;29(2):171-81
   PubMed Web of Science ®Google Scholar
• Pabinger I, Brenner B, Kalina U, Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 2008;6(4):622-31
   PubMed Web of Science ®Google Scholar
• Eerenberg ES, Kamphuisen PW, Sijpkens MK, Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124(14):1573-9
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Braunwald E. The year in non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol 2008;52(13):1095-103
   PubMed Web of Science ®Google Scholar
• The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337(10):657-62
   PubMed Web of Science ®Google Scholar
• Hirsh J, Warkentin TE, Shaughnessy SG, Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119(1 Suppl):64S-94S
   PubMed Web of Science ®Google Scholar
• Kagansky N, Knobler H, Rimon E, Safety of anticoagulation therapy in well-informed older patients. Arch Intern Med 2004;164(18):2044-50
   PubMed Web of Science ®Google Scholar
• Klein TE, Altman RB, Eriksson N, Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009;360(8):753-64
   PubMed Web of Science ®Google Scholar
• Pengo V, Cucchini U, Denas G, Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with non-valvular atrial fibrillation. Thromb Haemost 2010;103(2):442-9
   PubMed Web of Science ®Google Scholar
• Fuster V, Ryden LE, Cannom DS, ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114(7):e257-354
   PubMed Web of Science ®Google Scholar
• Denas G, Pengo V. Emerging anticoagulants. Expert Opin Emerg Drugs 2011;16(1):31-44
   PubMed Web of Science ®Google Scholar
• Bauersachs R, Berkowitz SD, Brenner B, Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363(26):2499-510
   PubMed Web of Science ®Google Scholar